Drug Trial Radar · NCT05422794
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
57
Planned (sponsor's estimate)
Start
May 18, 2023
Primary completion
Mar 31, 2027
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jun 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase Ib trial tests the safety and tolerability of ZEN003694 in combination with an immunotherapy drug called pembrolizumab and the usual chemotherapy approach with nab-paclitaxel for the treatment of patients with triple negative-negative breast cancer that has spread to other parts of the body (advanced). Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Immunotherapy with monoclonal antibodies, such as pembrolizumab may help the body's immune system attach the cancer and may interfere with the ability of tumor cells to grow and spread. ZEN003694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that over produce BET protein. Combination therapy with ZEN003694 pembrolizumab immunotherapy and nab-paclitaxel chemotherapy may help shrink or stabilize cancer for longer than chemotherapy alone.
Conditions
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Locally Advanced Triple-Negative Breast Carcinoma
- Metastatic Triple-Negative Breast Carcinoma
- Unresectable Triple-Negative Breast Carcinoma
Interventions
BET Bromodomain Inhibitor ZEN-3694Drug
Given PO
Biopsy ProcedureProcedure
Undergo biopsy
Biospecimen CollectionProcedure
Undergo collection of blood samples
Computed TomographyProcedure
Undergo CT
Magnetic Resonance ImagingProcedure
Undergo MRI
Nab-paclitaxelDrug
Given IV
PembrolizumabBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) of ZEN003694 (ZEN-3694) used in combination with pembrolizumab and nab-paclitaxelTime frame: Up to 28 days from start of treatment
- Recommended phase 2 dose (RP2D) of ZEN003694 (ZEN-3694) used in combination with pembrolizumab and nab-paclitaxelTime frame: Up to 28 days from start of treatment
- Incidence of adverse eventsTime frame: Up to 3 years from treatment start date
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Boston Medical Center
Boston, Massachusetts · Active not recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
NYU Langone Hospital - Long Island
Mineola, New York · Recruiting
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York · Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio · Recruiting
Vanderbilt Breast Center at One Hundred Oaks
Nashville, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.